Highlights,Elanco Animal Health reported a miss in earnings, with EPS falling short of expectations.,Analysts adjusted their ...

Elanco Animal Health Incorporated has entered into an agreement with South Dakota-based Medgene to leverage the company's ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with South Dakota-based ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...

Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...

Elanco Animal Health Inc (ELAN) reports robust organic growth and significant debt reduction, setting a positive outlook for ...

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.

A novel parasite protection therapy from Elanco Animal Health received FDA approval in October 2024, and was recently made available on the market with a launch at the 2025 Veterinary Meeting & Expo ...

Elanco Animal Health announced the establishment of an agreement with Medgene, a South Dakota-based biotechnology company, to utilize its advanced vaccine platform technology (baculovirus derived ...

Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.

Elanco Animal Health (NYSE:ELAN) stock falls as the company reports mixed Q4 2024 results, and sets 2025 outlook below consensus due to forex headwinds. Read more here.